Related Experiment Video

Updated: Jun 10, 2026

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis
08:01

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis

Published on: November 17, 2017

Apolipoprotein A-I and its mimetics for the treatment of atherosclerosis

Jonathan D Smith1

  • 1Cleveland Clinic, Department of Cell Biology, 9500 Euclid Avenue, Cleveland, OH 44195, USA. smithj4@ccf.org

Current Opinion in Investigational Drugs (London, England : 2000)
|August 24, 2010
PubMed

Insights

New therapies targeting high-density lipoprotein (HDL) show promise for reducing residual cardiovascular risk. Apolipoprotein A-I (apoAI) compounds and mimetic peptides may help regress atherosclerosis and stabilize plaques, though further development is needed.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Biochemistry

Background:

  • Statins reduce major adverse coronary events but leave significant residual risk.
  • High-density lipoprotein (HDL) and apolipoprotein A-I (apoAI) are linked to reduced coronary artery disease risk.
  • HDL/apoAI mechanisms include reverse cholesterol transport, offering therapeutic potential.

Purpose of the Study:

  • To review preclinical and clinical findings for apoAI-based atherosclerosis therapies.
  • To evaluate apoAI-containing compounds and apoAI mimetic peptides.
  • To identify potential clinical applications and development hurdles for these novel therapies.

Main Methods:

  • Review of preclinical studies on apoAI-based compounds and peptides.
  • Analysis of clinical trial data for these investigational therapies.
  • Assessment of mechanisms of action, including reverse cholesterol transport.

Main Results:

  • ApoAI-containing compounds and apoAI mimetic peptides demonstrate potential in preclinical and early clinical studies.
  • These therapies may promote atherosclerosis regression and plaque stabilization.
  • Further research is required to overcome development challenges.

Conclusions:

  • ApoAI-based therapies represent a promising frontier for addressing residual cardiovascular risk.
  • These approaches have the potential to be clinically useful in managing atherosclerosis.
  • Significant hurdles remain in developing safe and effective apoAI-based treatments.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...